Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions

A Prospective, Multicenter, Open-label Clinical Evaluation of the Effect of IV Zoledronic Acid 4mg on PAIN, QUALITY OF LIFE and TIME IN INFUSION CHAIR in Breast Cancer, Multiple Myeloma, and Prostate Cancer Patients With Cancer-related Bone Lesions

Patients with bone metastases or bone lesions caused by breast cancer, multiple myeloma or prostate cancer will be treated with IV Zometa in a 15 minute infusion. Pain will be evaluated, as well as time in chair, quality of life and safety of Zometa.

Inclusion Criteria

• Signed informed consent
• Greater than 18 years of age
• Proof of breast cancer, multiple myeloma or prostate cancer
• Diagnosis of at least one cancer-related bone lesion
• If patient is of child-bearing potential, negative pregnancy test and on a medically recognized form of contraception
• ECOG performance status of 0,1 or 2
• Ability to read, understand and write English or Spanish language
• Normal renal function
• Corrected serum calcium equal to or greater than 8mg/dl Exclusion Criteria
• clinically symptomatic brain metastases
• hypersensitivity to Zometa or other bisphosphonates
• pregnant or lactating